Dextromethorphan-bupropion-associated pharmacovigilance signals based on the FAERS database: An observational study.
Medicine June 26, 2026 Ruixue Liu, Chunxiao Liu, Chunhui Li et al.
Dextromethorphan-bupropion, a novel oral N-methyl-D-aspartate receptor antagonist approved by the Food and Drug Administration in August 2022, launched in the United States in October 2022 for major depressive disorder. We aimed to detect and characterize the adverse events (AEs) of dextromethorphan-bupropion using the FDA adverse event reporting system from the 4th quarter of 2022 to the 4th...